Literature DB >> 3987922

Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974.

L J Resseguie, J F Hick, J A Bruen, K L Noller, W M O'Fallon, L T Kurland.   

Abstract

Comparison of a cohort of 988 offspring exposed in utero to exogenous progestins with a matched cohort of unexposed offspring did not result in detection of an association of congenital anomalies with exposure. The conclusions are based primarily on outcomes of pregnancy with exposure to progesterone and 17 alpha-hydroxyprogesterone caproate, and may not apply to androgenic progestins. Offspring exposed to combinations of progestins and estrogens were excluded from this study and may have a different distribution of anomalies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987922     DOI: 10.1016/s0015-0282(16)48490-6

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  13 in total

Review 1.  Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.

Authors:  Jodie M Dodd; Rosalie M Grivell; Cecelia M OBrien; Therese Dowswell; Andrea R Deussen
Journal:  Cochrane Database Syst Rev       Date:  2017-10-31

Review 2.  Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.

Authors:  Maisa Feghali; Raman Venkataramanan; Steve Caritis
Journal:  Semin Perinatol       Date:  2014-09-23       Impact factor: 3.300

3.  Progesterone supplementation and the prevention of preterm birth.

Authors:  Errol R Norwitz; Aaron B Caughey
Journal:  Rev Obstet Gynecol       Date:  2011

4.  In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.

Authors:  Caitlin C Murphy; Piera M Cirillo; Nickilou Y Krigbaum; Barbara A Cohn
Journal:  Am J Obstet Gynecol       Date:  2021-11-09       Impact factor: 10.693

5.  Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.

Authors:  Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Gary D Hankins; Menachem Miodovnik; Mary F Hebert; Jason G Umans; Thomas Benedetti; Donald Mattison; Anne Zajicek; Dawn Fischer; Aimee Jackson
Journal:  Am J Obstet Gynecol       Date:  2012-08-16       Impact factor: 8.661

6.  Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study.

Authors:  Melanie A van Os; Jeanine A van der Ven; C Emily Kleinrouweler; Eva Pajkrt; Esteriek de Miranda; Aleid van Wassenaer; Martina Porath; Patrick M Bossuyt; Kitty Wm Bloemenkamp; Christine Willekes; Mallory Woiski; Martijn A Oudijk; Katia M Bilardo; Marko J Sikkema; Johannes J Duvekot; Diederik Veersema; Jacqueline Laudy; Petra Kuiper; Christianne Jm de Groot; Ben Willem J Mol; Monique C Haak
Journal:  BMC Pregnancy Childbirth       Date:  2011-10-24       Impact factor: 3.007

7.  Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.

Authors:  Jodie M Dodd; Rosalie M Grivell; Cecelia M OBrien; Therese Dowswell; Andrea R Deussen
Journal:  Cochrane Database Syst Rev       Date:  2019-11-20

8.  A randomized double-blind controlled trial of the use of dydrogesterone in women with threatened miscarriage in the first trimester: study protocol for a randomized controlled trial.

Authors:  Diana Man Ka Chan; Ka Wang Cheung; Sofie Shuk Fei Yung; Vivian Chi Yan Lee; Raymond Hang Wun Li; Ernest Hung Yu Ng
Journal:  Trials       Date:  2016-08-17       Impact factor: 2.279

9.  Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.

Authors:  Arianne C Lim; Kitty W M Bloemenkamp; Kees Boer; Johannes J Duvekot; Jan Jaap H M Erwich; Tom H M Hasaart; Pieter Hummel; Ben W J Mol; Jos P M Offermans; Charlotte M van Oirschot; Job G Santema; Hubertina C J Scheepers; Willem A Schöls; Frank P H A Vandenbussche; Maurice G A J Wouters; Hein W Bruinse
Journal:  BMC Pregnancy Childbirth       Date:  2007-06-19       Impact factor: 3.007

10.  Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.

Authors:  Alex C Vidaeff; Michael A Belfort
Journal:  Patient Prefer Adherence       Date:  2013-07-11       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.